The price of TG Therapeutics Inc (NASDAQ:TGTX) shares last traded on Wall Street rose 12.91% to $34.90.
TGTX stock price is now 42.99% away from the 50-day moving average and 82.18% away from the 200-day moving average. The market capitalization of the company currently stands at $5.43B.
With the price target of $50, TD Cowen recently initiated with Buy rating for TG Therapeutics Inc (NASDAQ: TGTX). On August 02, 2023, Goldman Upgraded its previous ‘Sell’ rating to ‘Neutral’ on the stock reducing its target price from $16 to quote $12, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Lonial Sagar, Director sold 5,000 shares of the company’s stock on Nov 11 ’24. The stock was sold for $152,200 at an average price of $30.44. Upon completion of the transaction, the Director now directly owns 100,195 shares in the company, valued at $3.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 11 ’24, Director Charney Laurence N sold 25,000 shares of the business’s stock. A total of $754,875 was realized by selling the stock at an average price of $30.20. This leaves the insider owning 212,479 shares of the company worth $7.42 million. A total of 10.87% of the company’s stock is owned by insiders.
During the past 12 months, TG Therapeutics Inc has had a low of $9.81 and a high of $32.48. As of last week, the company has a debt-to-equity ratio of 1.32, a current ratio of 4.59, and a quick ratio of 3.91. The fifty day moving average price for TGTX is $24.4067 and a two-hundred day moving average price translates $19.1574 for the stock.
The latest earnings results from TG Therapeutics Inc (NASDAQ: TGTX) was released for 2024-09-30. The net profit margin was -5.42% and return on equity was -8.05% for TGTX. The company reported revenue of $83.88 million for the quarter, compared to $165.81 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -49.41 percent.
